Trials / Recruiting
RecruitingNCT07135128
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Xiaorong Sun · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm clinical study to evaluate the safety, tolerability and preliminary efficacy of \[225Ac\]Ac-FAPI-XT injection in patients with FAP-positive advanced solid tumors.
Detailed description
A Clinical Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Efficacy of \[225Ac\]Ac-FAPI-XT Injection in FAP-positive Patients With Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 225Ac-FAPI-XT | Patients will receive \[225Ac\]Ac-FAPI-XT(XT117) administration at an interval of 6 weeks between each dose. |
Timeline
- Start date
- 2024-10-14
- Primary completion
- 2026-06-30
- Completion
- 2026-12-01
- First posted
- 2025-08-21
- Last updated
- 2025-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07135128. Inclusion in this directory is not an endorsement.